Modulating the Transport of Thiol-Containing Molecules for the Treatment of Lung Disease and Cancer
Tech ID: 02-16
Summary - National Jewish Health scientists have identified families of compounds that can increase the transport of thiol-containing molecules, like glutathione, from the cell. Glutathione is a critical thiol used by a large number of repair and detoxification pathways, particularly in the lung. Cystic fibrosis and a number of inflammatory lung diseases share a diminished level of glutathione in the epithelial lining fluid and excessive lung inflammatory responses. The compounds identified increase endogenous glutathione in the epithelial lining fluid and therefore could decrease oxidative damage in these diseases. Increasing glutathione efflux is also beneficial in sensitizing cancer cells, which are characterized by increased intracellular levels of glutathione and increased levels of multidrug resistance-associated proteins (MRPs) that transport glutathione, to anti-cancer agents that cause oxidative damage. These discoveries form the basis of a novel drug discovery platform that modulates oxidative stress in human disease.
- Lung diseases, such as cystic fibrosis, chronic beryllium disease, sarcoidosis, idiopathic pulmonary fibrosis, acute respiratory distress syndrome, chronic obstructive lung diseases, idiopathic interstitial pneumonia, and diffuse fibrosing alveolitis.
- Adjuvant therapeutic in radiation or chemotherapy treatment for cancer.
Advantages of Invention
- Many of the compounds are well known and characterized, including one that is currently approved and marketed for unrelated indications.
- Compartment and tissue specific secretion of thiol-containing molecules.
- An improvement over treatment with exogenous glutathione, which has a short half-life, poor bioavailability, and a lack of stability.
State of Development - In mice, treatment with these compounds increased the levels of glutathione in the extracellular compartment and the lung epithelial lining fluid (ELF). Significant MRP-specific efflux of glutathione has also been demonstrated in cancer cell lines with a concomitant potentiation of cisplatin cytotoxicity.
- Day BJ et al. Infect Immun. 2004 Apr; 72(4):2045-51. PMID: 15039325
- Day BJ et al. Am J Physiol Lung Cell Mol Physiol. 2001 Jul; 281(1):L31-8. PMID: 11404242
- Kachadourian et al. Int J Oncol. 2007 Jul; 31(1):161-8. PMID: 17549417
- Kachadourian et al. Biochem Pharmacol. 2007 Dec 15; 74(12):1677-85. Epub 2007 May 21. PMID: 17585883
- Kachadourian et al. Free Rad Bio & Med 2006; 41:65-76. PMID: 16781454
Patent - Issued U.S. Patent #7,498,047
Published U.S. Patent Application #20060135585; International Publication #WO2004/042020; other U.S. and international patents pending.
Inventors - Brian Day, PhD, Leonard Velsor, PhD and Remy Kachadourian, PhD
Licensing Status - This technology is available for licensing.
For Further Information, Contact:
Emmanuel Hilaire, PhD
Technology Transfer Office
National Jewish Health
1400 Jackson Street, Room M206b
Denver, CO 80206